IRB Study Number 18-486
Status Recruiting
Location Cleveland Clinic Main Campus
Institute Taussig Cancer Institute
Description
Objectives:
- Assess evidence of recurrent presence of acellular lymphoma cell-specific clonotypic immunoglobulin-encoding circulating tumor DNA (ctDNA) in pediatric and AYA (0-39 years of age) patients with cHL.
- Estimate correlation of ctDNA levels with other previously characterized lymphoma-associated antigens, such as sCD30) and Thymus and TARC/CCL17 in pediatric and AYA cHL patients.
- Assess correlation between changes in serum concentrations of ctDNA, sCD30, TARC and magnitude of the therapy-induced antitumor clinical responses in pediatric and AYA cHL patients measured by conventional functional imaging.
Inclusion Criteria
Patients with newly diagnosed classical cHL age: 5-39 years
Exclusion Criteria
Patients with newly diagnosed classical cHL age: 5-39 years
